EUVIMEDEUVIMED entdecken
Open Access

Gut microbial resistance and metabolism of selective serotonin reuptake inhibitors drive multidrug resistance and contribute to antidepressant tachyphylaxis

Ming-Che Cheng, Hsiao-Ching Lin, Chia-Ching Liaw, Yu-Chi Lin, Po-Hsiu Kuo, Chieh-Chang Chen, Ming-Shiang Wu, Shoei-Sheng Lee, Chia-Chuan Chang

Drug Metabolism and Disposition · 2026-05 · 54 (5) · 100273

DOI: 10.1016/j.dmd.2026.100273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-05. Verfasst von Ming-Che Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Sertraline, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Taiwan Ministry of Science and Technology, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective serotonin reuptake inhibitors (SSRIs) are among the most widely used antidepressant medications in modern clinical practice. However, the underlying mechanisms of the rapid onset of tolerance to antidepressants (antidepressant tachyphylaxis [ADT]) led by SSRIs are not well-investigated. To clarify the roles of the interaction between gut microbes and SSRIs in the development of ADT and other adverse effects, we isolated 4 sertraline (STR; an SSRI)-resistant microbial strains, one of which was identified as uropathogenic Escherichia coli (E coli G5100a). Through transcriptomic analysis and multidrug efflux pump antagonism assays, resistance-nodulation-division-type and partially ABC-type multidrug efflux pumps were confirmed as the primary mechanisms by which E coli G5100a resists STR toxicity. The upregulation of these genes also led to increased resistance to chloramphenicol, rifampicin, and β-lactam-type antibiotics. Furthermore, Global Natural Product Social Molecular Networking-based metabolite analysis and liquid chromatography-mass spectrometry profiling revealed that E coli G5100a metabolized approximately 25% of STR in the culture medium. Two major STR metabolites were isolated and structurally elucidated as STR ketone (1) and N-acetylsertraline (2) using NMR and mass spectrometry analyses. Using the DeePred-BBB model, we confirmed that none of the putative SSRI-related metabolites were able to pass through the blood-brain barrier. These findings suggest that STR may induce multidrug resistance in gut microbiota, potentially contributing to clinical SSRI-related side effects and ADT. This study provides a novel perspective on the origins of SSRI-induced side effects in clinical settings, offering new insights for the future development of central nervous system-targeted pharmaceuticals. SIGNIFICANCE STATEMENT: Selective serotonin reuptake inhibitors may alter the composition of the intestinal microbiota. Specific gut microbes are likely to express metabolic resistance genes in response to selective serotonin reuptake inhibitor induction. The potential mechanisms in the development of SSRI tolerance from the perspective of the gut microbiome were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsAntidepressive AgentsSertralineGastrointestinal MicrobiomeDrug Resistance, Multiple, BacterialUropathogenic Escherichia coliHumansAnimalsAnti-Bacterial Agents

Stichwörter der Autor:innen

Gut microbesMetabolismMultiple-drug resistanceSelective serotonin reuptake inhibitorsSertraline

Substanzen

Selective Serotonin Reuptake InhibitorsAntidepressive AgentsSertralineAnti-Bacterial Agents

Autor:innen und Institutionen

  • School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China.
  • Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan, Republic of China.
  • Division of Chinese Materia Medica Development, National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, Republic of China.
  • Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China.
  • Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan, Republic of China.
  • School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China. Electronic address: chiachang@ntu.edu.tw.

Förderung

  • Taiwan Ministry of Science and Technology
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Cheng, M. C., Lin, H. C., Liaw, C. C., Lin, Y. C., Kuo, P. H., Chen, C. C., Wu, M. S., Lee, S. S., & Chang, C. C. (2026). Gut microbial resistance and metabolism of selective serotonin reuptake inhibitors drive multidrug resistance and contribute to antidepressant tachyphylaxis. Drug Metabolism and Disposition, 54(5), 100273. https://doi.org/10.1016/j.dmd.2026.100273

Vancouver

Cheng MC, Lin HC, Liaw CC, Lin YC, Kuo PH, Chen CC, et al. Gut microbial resistance and metabolism of selective serotonin reuptake inhibitors drive multidrug resistance and contribute to antidepressant tachyphylaxis. Drug Metabolism and Disposition. 2026;54(5):100273. doi:10.1016/j.dmd.2026.100273

BibTeX
@article{Cheng2026,
  author = {Cheng, Ming-Che and Lin, Hsiao-Ching and Liaw, Chia-Ching and Lin, Yu-Chi and Kuo, Po-Hsiu and Chen, Chieh-Chang and Wu, Ming-Shiang and Lee, Shoei-Sheng and Chang, Chia-Chuan},
  title = {Gut microbial resistance and metabolism of selective serotonin reuptake inhibitors drive multidrug resistance and contribute to antidepressant tachyphylaxis},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {5},
  pages = {100273},
  doi = {10.1016/j.dmd.2026.100273}
}
Kostenlos starten →